A large body of evidence suggests that the neuropeptide galanin plays an important role in seizure control. In line with this, it was demonstrated that the galanin analogue, NAX-5055, exerts a potent anticonvulsant activity in animal seizure models. We recently found that the NAX-5055-mediated anticonvulsant action involves modulation of both excitatory and inhibitory neurotransmission. Since homeostasis of neurotransmitters and cerebral energy metabolism are intimately linked, it was investigated whether the effects of NAX-5055 on neurotransmission involve changes in energy metabolism and in particular glucose-and amino acid metabolism. With this aim, cultured neurons from mouse brain were incubated with [U-13 C]glucose in absence or presence of NAX-5055. Since effects of NAX-5055 on neurotransmission were detected during repetitive stimulation, we tested potential metabolic effects while mimicking repetitive bursts of neurotransmitter release as occurring in the intact brain. The metabolic pathways were mapped using gaschromatography coupled to mass-spectrometry. We found that NAX-5055 does not modify glucose metabolism in glutamatergic and GABAergic neurons. Furthermore, the effect of NAX-5055 on astrocyte-neuron metabolic interactions was investigated by incubating cocultures of astrocytes and either glutamatergic or GABAergic neurons with [U-13 C]glucose or the glialselective substrate [1,[2][3][4][5][6][7][8][9][10][11][12][13] C]acetate, with or without NAX-5055. In the presence of NAX-5055, no changes in the metabolic landscape were traced. The findings suggest that the anticonvulsant action of NAX-5055 and the accompanying changes in neurotransmission do not involve alterations in energy and amino acid metabolism. Hence, NAX-5055 appears to be an anti-seizure drug candidate displaying no unwanted side effects concerning brain energy and amino acid homeostasis. V C 2017
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INTRODUCTION
For proper brain function, a fine-tuned balance between excitatory and inhibitory activity must be maintained (Attwell and Laughlin, 2001; Bak et al., 2006) . Two main players contribute to such balance at the SIGNIFICANCE Several studies in animal models of seizures and epilepsy have demonstrated that the neuropeptide galanin has potent anticonvulsant effects. In line with this, galanin analogues have been designed to specifically target the galanin system and mimic its anti-seizure effects. NAX-5055 is one of these analogues with proven efficacy against experimentally induced seizures, efficient brain-penetrability, and receptor specificity. Here we demonstrate that the anticonvulsant action of NAX-5055 and the accompanying changes in excitatory and inhibitory neurotransmission do not involve alterations in cerebral energy metabolism. The results indicate that NAX-5055 could be safely tested in clinical trials without negatively affecting cerebral metabolism. neurotransmitter level, the excitatory amino acid glutamate, and the inhibitory transmitter g-aminobutyric acid (GABA). Thus, neurotransmission and homeostasis of glutamate and GABA must be highly regulated and controlled. Particularly, the inactivation process of these neurotransmitters is primarily maintained by high affinity transporters located on the pre-synaptic neurons and adjacent astrocytic processes that remove neurotransmitter from the synaptic cleft (Schousboe, 2003; Schousboe et al., 2013) . To the extent that neurotransmitters and in particular glutamate, are taken up by astrocytes (Danbolt, 2001; Gegelashvili and Schousboe, 1998; Rothstein et al., 1996; Schousboe and Hertz, 1981) , the neurotransmitter pools are depleted, and this renders a need for replenishment. Interestingly, neurons lack pyruvate carboxylase, which is quantitatively the most important anaplerotic enzyme in the brain, making them incapable of de novo synthesis of glutamate and GABA from glucose (Hertz et al., 1999; Patel et al., 1974; Schousboe et al., 1997; Shank et al., 1985; Yu et al., 1983) . The metabolic incapability of the neurons is compensated for by a supply of a precursors formed in the astrocytes and it has repeatedly been demonstrated that glutamine represents the quantitatively most important precursor for biosynthesis of glutamate and GABA (Schousboe et al., 2013; Waagepetersen et al., 2001 Waagepetersen et al., , 2003 Waagepetersen et al., , 2005b Waagepetersen et al., , 2007 . This underlines the existence of an interdependent relationship between astrocytes and neurons for maintenance of brain function (Schousboe et al., 2013) .
The processes associated with cerebral function and particularly neurotransmission are energy demanding (Attwell and Gibb, 2005; Attwell and Laughlin, 2001; Jolivet et al., 2009) . Glucose is the primary substrate for energy generation in the brain where it is mainly oxidatively metabolized (McKenna et al., 2012; Shulman et al., 2001) , and therefore, the brain is highly dependent upon a continuous supply of glucose and oxygen from the blood. Moreover, it has been shown that the level of cerebral activity determines cerebral glucose consumption (Hyder et al., 2006; Sibson et al., 1998) . Utilization of several other energy substrates including glutamate and GABA may also contribute and affect metabolism and energy generation. Complete oxidative degradation of glutamate and GABA requires subsequent astrocytic anaplerosis of tricarboxylic acid (TCA) cycle intermediates for maintenance of neurotransmitter homeostasis. Accordingly, energy metabolism and (neurotransmitter) amino acid homeostasis are intimately linked and these mechanisms are unlikely to operate independent of each other (Schousboe et al., 2013) .
Seizure activity is characterized by hyperexcitability of brain tissue and is thought to arise as a consequence of disturbances in the balance of excitatory and inhibitory activity (Sonnewald and Kondziella, 2003) . A large body of evidence suggests that the neuropeptide galanin plays an important role in seizure control particularly through its modulatory actions on excitatory neurotransmission (Mazarati et al., 2000 (Mazarati et al., , 2001 Mazarati, 2004; McColl et al., 2006; Zini et al., 1993) . For instance, it was demonstrated that galanin increases seizure threshold and reduces seizure duration and severity in galanin and galanin receptor 1 (GalR1) knockout mice and in different epilepsy animal models (Mazarati et al., 2000; McColl et al., 2006; Mitsukawa et al., 2008) . Furthermore, Zini et al. (1993) showed that galanin inhibited depolarizationinduced release of glutamate in the hippocampus, a brain structure particularly vulnerable to seizure generation. Although galanin has been demonstrated to be an effective inhibitor of seizure activity (Mazarati, 2004; Mazarati et al., 2000 Mazarati et al., , 2001 McColl et al., 2006; Zini et al., 1993) , attempts to pharmacologically target the galanin system have been limited due to the poor bioavailability that peptides display in general and the impermeability of the blood-brain barrier (BBB) to galanin. In order to develop galanin-based anticonvulsant agents, Bulaj and colleagues (2008) rationally designed a family of galanin analogues. Among this group, the analogue NAX-5055 was found to effectively restrict seizure activity in a variety of animal models of partial seizures suggesting a potential use in the treatment of pharmacoresistant epilepsy (White et al., 2009) . NAX-5055 crosses the BBB, displays a low nanomolar affinity for galanin receptors, particularly the subtype GalR1, and is metabolically stable with a half-life of 9.4 hours in rat serum (Bulaj et al., 2008) . Furthermore, NAX-5055 was found to be biologically active after intravenous, intraperitoneal, and subcutaneous administration, and its efficacy was associated with a linear pharmacokinetic profile. It is worth mentioning that NAX-5055 exhibited potent anticonvulsant effects at doses that did not cause notable behavioral toxicity (White et al., 2009) . Taken together, the molecular and functional characteristics of NAX-5055 make it a promising anti-seizure drug candidate.
We recently found that the effect of NAX-5055 at the cellular level involves modulation of both excitatory and inhibitory neurotransmission. In particular, NAX-5055 in a nanomolar concentration range reduces vesicular release of glutamate and lowers the extracellular concentration of glutamate while it elevates the extracellular GABA level in primary cultures of neurons (Walls et al., 2016) . As described above, brain energy metabolism, (neurotransmitter) amino acid homeostasis and cerebral activity are intimately linked events, and it is unlikely that alterations observed in neurotransmission exist independent of changes in energy metabolism and in particular glucose metabolism. Since disturbances in cerebral glucose metabolism may lead to severe dysfunction (CabezasOpazo et al., 2015; Liot et al., 2016; Sun et al., 2016; Zsurka and Kunz, 2015) it is important to clarify any changes in brain metabolism that NAX-5055 may cause in order to further evaluate the potential of this galanin analogue as an anticonvulsant candidate. It was therefore investigated if NAX-5055 might exert effects on cellular metabolism under stimulated and non-stimulated conditions employing cultures of glutamatergic and GABAergic neurons. Moreover, using a neuron-astrocyte co-culture system (Leke et al., 2008) , it was examined whether NAX-5055 exhibited any effect on the metabolic interactions known to exist between astrocytes and neurons, in particular the transfer of glutamine from astrocytes to neurons.
MATERIALS AND METHODS

Source of Materials
NMRI mice were obtained from Janvier Labs and were delivered to the Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen where they were euthanized and prepared for experimentation. The plasticware for cell culturing was from NUNC A/S. Dulbecco's modified Eagle's medium (DMEM) powder, poly-D-Lysine, N-methyl-D-aspartate (NMDA), N-methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide (MTBSTFA), and N,N-dimethylformamide (DMF) were purchased from SigmaAldrich. Fetal calf serum (FCS) was from Gibco, Life Technologies. [U- Isotopes Laboratories Inc., were also used. Gas chromatographymass spectrometry chemicals and chromatography columns were purchased from Phenomenex. All other chemicals were of the purest grade available and purchased from regular commercial suppliers. The galanin analogue NAX-5055 was synthesized according to procedures described previously (Bulaj et al., 2008) and was kindly provided by Dr. Grzegorz Bulaj, University of Utah, and Dr. Brian Klein, NeuroAdjuvants, Inc. NAX-5055 ([Sarcosine] WTLNSAGYLLGPKK [Lysine-palmitoyl] K) was designed as a truncated galanin (GWTLNSAGYLLG-PHAVGNHRSFSDKNGLTS) analogue in which nonessential amino acid residues were removed or replaced with Lys and lipoamino acid residues (Bulaj et al., 2008) .
Cell Cultures
All efforts were made to reduce the number of animals used and to minimize animal suffering.
Cerebellar granule cells were isolated from 7-day-old mice of mixed genders and cultured as described by Schousboe et al. (1989) . A total of 8 different litters, comprising 10-12 pups per litter, were used. Cerebral neocortical cells were isolated from 15-day-old mouse embryos, gender unknown, and cultured as described by Hertz et al. (1989) , with minor modifications. For the experiments with neocortical cells, 6 different pregnant mice (10-12 embryos per mouse) were used. The procedure for primary culture preparation has been comprehensively described elsewhere (Walls et al., 2014) . Cells were seeded in poly-D-lysine-coated Petri dishes (35 mm/2 ml) at a density of 2.5-2.75 X 10 6 cells/ml and maintained in slightly modified DMEM (Hertz et al., 1982) containing 12 mM glucose, 10 % (v/v) FCS and in the case of cerebellar neurons, 50 mM kainic acid. The cultures were kept in atmospheric air containing 5% CO 2 at 37 8C. After 48 h in culture, cytosine arabinoside (20 mM, final concentration) was added to the medium to prevent astrocytic proliferation in the neuronal cultures. Further, on days 2 and 5, glucose was added to the culture medium to a final concentration of minimum 12 mM. Cells were cultured for 7-8 days at which time the cultures from cerebellum consist of 90 % glutamatergic neurons while the cultures from cerebral neocortex consist of 70 % highly differentiated GABAergic neurons that release the neurotransmitter upon depolarization (Belhage et al., 1993; Drejer et al., 1987; Larsson et al., 1983; Snodgrass et al., 1980) . Therefore, these cultures constitute a valid experimental model system to study glutamatergic and GABAergic neurons, respectively.
To obtain co-cultures of cerebellar and cortical neurons and astrocytes, the method described above to prepare neuronal primary cultures was used with the omission of cytosine arabinoside from the culture medium, thereby allowing for astrocyte proliferation. This strategy provides a system suitable for studying interactions between astrocytes and neurons (Leke et al., 2008) . In the experiments using co-cultures from cerebellum, 3 different litters were used while for the experiments using neocortical cells, 3 additional pregnant mice (10-12 embryos per mouse) were employed.
Incubation experiments using 13 C-labeled substrates. First, it was investigated whether NAX-5055 affected cellular metabolism under non-stimulated conditions. Regardless of the type of neuronal culture, the experimental procedure was as follows. The culture medium was removed and the cells were washed once with 1 ml of phosphatebuffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 7.3 mM Na 2 HPO 4 , 0.9 mM CaCl 2 , and 0.5 mM MgCl 2 , pH 7.4, 37 8C). Cultures of neurons or co-cultures of neurons and astrocytes were subsequently incubated for 60 min at 37 8C in 2 ml serum-free DMEM culture medium containing 2.5 mM [U-
13 C]glucose (0 nM NAX-5055). Additional cell cultures were incubated in a similar medium also containing NAX-5055 at concentrations of 1 or 100 nM (dissolved in double distilled H 2 O). These concentrations were chosen because they span the range in which NAX-5055 was found to decrease vesicular glutamate release and to increase GABA extracellular concentrations in primary cultures (Walls et al., 2016) . Another set of experiments was performed to investigate whether NAX-5055 was able to alter the metabolic interaction between neurons and astrocytes. For this purpose, cerebellar and cortical co-cultures were incubated in medium containing 2.5 mM [1,2-13 C]acetate plus 2.5 mM unlabeled glucose in the absence or presence of 1 or 100 nM NAX-5055. After the incubation, the medium was collected and the cells were washed twice with ice cold PBS, lysed, and extracted with 70% ethanol. The cells were scraped off the dish and centrifuged at 20,000 g for 20 min (4 8C) to separate the soluble extract (supernatant) from the insoluble components (pellet). Cell extracts were lyophilized and reconstituted in water for subsequent mass spectrometry analyses.
Superfusion experiments using 13 C-labeled substrates. Taking into account that the functional effect of NAX-5055 was observed under stimulated conditions and metabolism of neurotransmitter glutamate and GABA is linked closely to energy metabolism, the effects of NAX-5055 on energy metabolism of neuronal cultures or co-cultures of neurons and astrocytes were also examined under depolarizing conditions. As briefly described by Drejer et al. (1987) , dishes containing the cultures were transferred to a superfusion system, the cells were then covered with a nylon mesh (pore size 80 mm), and superfused with a HEPES buffer (HEPES 10 mM, CaCl 2 1.5 mM, NaCl 135 mM, and KCl 5 mM) containing 2.5 mM glucose at a flow of 2 ml/min. After 10 minutes of equilibration by superfusion, the medium was replaced by one containing 2.5 mM [U-
13 C]glucose with or without NAX-5055 (1 or 100 nM). In addition, depolarization was induced for 30 seconds every 4 minutes for a total of 8 stimulations. In cerebellar neurons, vesicular glutamate release was induced by 300 mM NMDA, an agonist of glutamate receptors that is not used as metabolic substrate and 10 mM glycine. When studying cerebral cortical neurons, depolarization was induced by a medium containing a high potassium concentration (55 mM K 1 , with an equimolar decrease in Na 1 ) because in these cultures the combination of NMDA and glycine also stimulates GABA release via reversal of GABA transporters, while GABAergic vesicular release is selectively induced by 55 mM K 1 (Belhage et al., 1993; Waagepetersen et al., 2001) . At the end of an experiment (48 min total superfusion time), the remaining medium was removed from the dishes and the cells were lysed and extracted as described for the incubation experiments. In an additional set of experiments, co-cultures were, after the equilibrium period, superfused with a medium containing 2.5 mM [1,2-13 C]acetate plus 2.5 mM unlabeled glucose in the absence or presence of 1 or 100 nM NAX-5055 and intermittently stimulated, as described above.
Metabolic mapping using gas chromatographymass spectrometry (GC-MS). Lyophilized cell extracts were reconstituted in water and an aliquot was adjusted to pH 1-2 with HCl and evaporated to dryness under nitrogen flow. Analytes/metabolites were extracted into an organic phase (96% ethanol/benzene) followed by derivatization with 14% DMF/86% MTBSTFA employing a procedure modified from Mawhinney et al., (1986) as described in detail in Walls et al. (2014) . A standard containing a mixture of unlabeled metabolites of interest and cell extracts were analyzed in a gas chromatograph (Agilent Technologies 7820A chromatograph, J&W GC column HP-5MS, parts no. 19091S-433) coupled to a mass spectrometer (Agilent Technologies, 5977E). The isotopic enrichment of the metabolites of interest was corrected for natural abundance of 13 C obtained from the unlabeled standards and calculated according to Biemann (1962) and Walls et al. (2014) . Data in Figs. 1 and 2 are presented as molecular carbon labeling (MCL), an average of total 13 C enrichment in 100 Fig. 1 . NAX-5055 does not alter glucose metabolism in glutamatergic and GABAergic neurons under non-stimulated and depolarized conditions. The molecular carbon labeling (MCL) in percent is presented as a measure of total 13 C-enrichment in lactate (lac) and alanine (ala) and several intermediates and amino acids namely citrate (cit), a-ketoglutarate (a-kg), glutamate (glu), glutamine (gln), GABA, fumarate (fum), malate (mal) and aspartate (asp), obtained following metabolism of [U-
13 C]glucose via glycolysis and TCA cycle. Cultures of cerebellar glutamatergic (A, C) and brain cortex GABAergic neurons (B, D) were incubated (60 min A, B) or continuously superfused (48 min C, D) with [U-
13 C]glucose(2.5 mM) in the absence (NAX-5055 0 nM, white bars) and presence of 1 nM (gray bars) or 100 nM (black bars) NAX-5055. To induce depolarization (C, D), in the superfusion system the medium was changed every 4 minutes to a medium containing either 300 mM NMDA and 10 mM glycine (glutamatergic neurons) or 55 mM K 1 (GABAergic neurons). Cell extracts were analysed using GC-MS for determination of the percentage distribution of 13 C labeled metabolites (for details see Materials and Methods). Results are averages 6 SEM (n54) obtained from at least 16 dishes from 4 different cell batches (4 dishes per batch) for each primary neuronal culture type in a specific condition. Data were statistically analyzed using Twoway analysis of variance (ANOVA) followed by Bonferroni's multiple comparison tests. No differences were found (P<0.05).
molecules of a given metabolite (Bak et al., 2006) . The MCL is calculated by multiplying the labeling (%) of the different isotopomers of a compound with the number of labeled atoms in that particular isotopomer, summing these products, and dividing them by the total number of carbon atoms found in 100 molecules of the relevant compound. Results in Fig. 3 are presented as labeling (%) of M 1 X, where M is the mass of the unlabeled molecule and X is the number of labeled C-atoms in a given isotopomer (Walls et al., 2014) .
Statistical Analysis
All statistical analyses were performed in GraphPad Prism 6.0 (GraphPad Software). By performing a D'Agostino-Pearson normality test verified data were normally distributed (P > 0.05). Furthermore, the Bartlett's test for equal variances showed that the variances did not differ significantly (P > 0.05). Paired, twotailed Student's t-test was employed when comparing two sets of data. Two-way analysis of variance (ANOVA) followed by Bonferroni's multiple comparison tests were performed if three or more groups of data were analyzed. P < 0.05 was considered statistically significant. Results are presented as averages 6 standard error of the mean (SEM). For statistical analysis, one replicate was considered to be a cell batch (cerebellar) isolated from one litter (comprising 10-12 pups per litter), or a cell batch (neocortical) isolated from one pregnant mouse (10-12 embryos per batch). For each experimental condition, at least three replicates were performed. Therefore, statistical evaluations were performed based on the following replicates. Briefly, in the experiments using cerebellar and neocortical neurons incubated or superfused with [U- 
RESULTS
Glucose Metabolism in Cerebellar and Cortical Neurons
In order to investigate the possible effects of NAX-5055 on neuronal glucose utilization under nonstimulated conditions, cultures of glutamatergic and GABAergic neurons from mouse cerebellum and brain cortex, respectively, were incubated in a medium containing the labeled substrate [U- Fig 1-3 ) from the group of control cells (0 mM NAX-5055) and cells treated with NAX-5055 under each experimental condition was pooled and statistically analysed. Paired, two tailed Student s t tests were performed; P values a between cerebellar and cortical neurons; b between cerebellar and cortical co-cultures. The bold numbers indicate statistical significance (P < 0.05). Fig. 3 . NAX-5055 did not modify the cerebellar or cortical metabolic interaction between neurons and astrocytes under resting and stimulated conditions. Intracellular 13 C-labeling patterns in metabolites that arise from a first turn and second turn of the TCA cycle following [1,2-13 C]acetate metabolism in cell co-cultures from either cerebellum (A, C) or brain cortex (B, D). Cell cultures were incubated (A, B) or superfused (B, D) with [1,2-13 C]acetate (2.5 mM) and unlabeled glucose (2.5 mM) in the absence (NAX-5055 0 nM, slashed white bars) and presence of 1 nM (slashed gray bars) or 100 nM (slashed black bars) NAX-5055 and treated as described in Fig. 1 and Material and Methods.
13 C-labeling obtained after [1,2-13 C]acetate metabolism was detected in the different isotopomeres of the TCA cycle intermediates and amino acids namely, citrate (cit), a-ketoglutarate (a-kg), glutamate (glu), glutamine (gln), GABA, fumarate (fum), and aspartate (asp). Data are presented as labeling (%) of M 1 X, where M is the mass of the unlabeled metabolite and X is the number of 13 C-labeled carbon atoms. Results are averages 6 SEM (n53) obtained from at least 12 dishes from 3 different cell batches (4 dishes per batch) for each coculture type in a specific condition. labeling in lactate, amino acids and tricarboxylic acid (TCA) cycle intermediates arising from metabolism of [U-13 C]glucose was obtained from neurons incubated in absence and presence of NAX-5055 (1 and 100 nM) and is presented as the molecular carbon labeling (MCL), an average of total 13 C enrichment in a given molecule (Fig. 1) . The MCL patterns were similar in cerebellar and cortical neurons regardless of the presence of NAX-5055 under non-stimulated conditions. However, as shown in Fig. 1B , a trend towards a dose-dependent increase in MCL induced by NAX-5055 was observed in cortical neurons.
As previously mentioned, NAX-5055 reduces the depolarization-induced vesicular release of glutamate and increases the extracellular concentration of GABA. Therefore, it was next tested whether NAX-5055 might affect glucose metabolism when the neurons were exposed to repetitive stimulation. Due to the tight correlation between cerebral activity and glucose consumption described in the introduction, we hypothesize that modulating the cellular activity by employing NAX-5055 during repetitive depolarization would also influence the glucose consumption. Hence, cerebellar or cortical neuronal cultures were intermittently exposed to a depolarizing medium to selectively induce vesicular neurotransmitter release. Unexpectedly, NAX-5055 did not modify the 13 C labeling patterns in cerebellar or cortical neurons when vesicular release of neurotransmitters was induced (Figs. 1C,D) . As shown in Table  I , the 13 C enrichment in most of the TCA cycle intermediates obtained from cerebellar neurons (Figs. 1A,C) was higher in comparison to that in the cortical neurons (Figs.  1B,D) . This indicates that glutamatergic neurons exhibits a higher TCA cycle activity under depolarized conditions than cortical neurons while the glycolytic rate is at a comparable level in the two types of neuronal cultures.
Glucose and Acetate Metabolism in Cerebellar and Cortical Co-cultures
Neuronal metabolism is tightly coupled to astrocyte metabolic functions. To investigate the possibility that NAX-5055 could be affecting the metabolic interaction between neurons and astrocytes, we tested its effects on metabolism of [U-13 C]glucose (2.5 mM) in co-cultures of neurons and astrocytes. NAX-5055 at the two concentrations tested (1 and 100 nM), did not alter the 13 C labeling in lactate, amino acids or TCA cycle metabolites of cerebellar or cortical neurons and astrocytes under nonstimulated or depolarized conditions (Fig. 2) . Again, the 13 C enrichment in most of the TCA cycle intermediates obtained from cerebellar neurons and astrocytes was higher (Table I) Data (presented in Fig 1-3 ) from the group of control cells (0 mM NAX-5055) and cells treated with NAX-5055 under each experimental condition was pooled and statistically analysed. Paired, two tailed Student s t tests were performed; P values between non-stimulated and stimulated conditions. The bold numbers indicate statistical significance (P < 0.05).
included. As shown in Fig. 3 , NAX-5055 was incapable of altering the labeling distribution in metabolites following acetate metabolism in cerebellar and cortical co-cultures under non-stimulated and depolarized conditions. Finally, it is worth noticing that a lower labeling in TCA cycle metabolites and amino acids was found in neuronal cultures and co-cultures under stimulated conditions compared to the non-stimulated conditions (Table II) .
DISCUSSION
The present study demonstrates that neuronal and astrocytic energy metabolism is unaffected by the novel anti-seizure neuropeptide NAX-5055, at concentrations within the range found to modify glutamate and GABA neurotransmission in primary cultures from mouse brain (Walls et al., 2016) . Our findings suggest that the previously observed effects of NAX-5055 on excitatory and inhibitory neurotransmission associated with its antiseizure action do not involve changes in cellular energyand amino acid metabolism in the brain.
NAX-5055 belongs to a family of rationally designed analogues of the ubiquitous neuropeptide galanin. It has been shown that upon specific activation of the galanin receptor GalR1, galanin is able to modulate both glutamatergic and GABAergic neurotransmission (Mazarati et al., 2000; McColl et al., 2006; Zini et al., 1993) conferring a potent anticonvulsant activity to this neuropeptide. Accordingly, agonists targeting GalR1 are likely to be suitable therapeutic agents against seizure activity and possibly epileptogenesis (Mazarati, 2004; Mazarati et al., 2000 Mazarati et al., , 2001 Mazarati et al., , 2006 McColl et al., 2006; Mitsukawa et al., 2008) . In line with this, NAX-5055 which displays a receptor subtype specificity for GalR1 approximately 15 times higher than GalR2 (Ki values are 3.5 nM and 51.5 nM for GalR1 and GalR2, respectively), was found to protect against seizures in three different mouse models of epilepsy (Bulaj et al., 2008; White et al., 2009) . Recently, using the same preparation of primary cultures of glutamatergic and GABAergic neurons as employed in the present study, the anticonvulsant effect of NAX-5055 was shown to be associated with a decrease in glutamatergic excitatory activity accompanied by an increase in GABA levels. Furthermore, an electrophysiological characterization of the NAX-5055 inhibitory effects on excitatory synaptic activity suggested that NAX-5055 targets the presynaptic component of the glutamatergic synapse possibly via galanin receptor activation, in particular GalR1 (Walls et al., 2016) .
The reduction in vesicular release of glutamate mediated by NAX-5055 (Walls et al., 2016) was hypothesized to be associated with lower energy requirement and hence attenuated glucose uptake and metabolism in glutamatergic neurons. Thus, a decreased labeling in metabolites obtained from glycolysis and TCA cycle was expected in the primary cultures of glutamatergic neurons superfused with NAX-5055. However, when glutamatergic neurons were incubated in the presence of [U-13 C]glucose, we found similar labeling patterns in lactate and alanine, as indicators of glycolytic activity, as well as in the TCA cycle intermediates in the absence or presence of NAX-5055. The lack of effect of NAX-5055 was irrespective of neuronal activity since NAX-5055 did not modify [U-
13 C]glucose metabolism either under non-depolarized conditions or when neurotransmitter release was stimulated. This provides robust support to the notion that NAX-5055 does not affect energy metabolism at least in primary cultures of glutamatergic neurons. On the other hand, in GABAergic neurons a trend towards a dose-dependent increase induced by NAX-5055 was observed in metabolite labeling after [U-13 C]glucose metabolism which may indicate an increased energy metabolism in the cortical GABAergic neurons in the presence of NAX-5055. It may be speculated that the elevated extracellular GABA concentration previously observed (Walls et al., 2016) may be associated with an increased metabolic activity of GABAergic neurons in the presence of NAX-5055.
The concentrations of NAX-5055 used in the present study (1 and 100 nM) are within the range of Ki values for GalR1 (Bulaj et al., 2008) as well as in the range in which NAX-5055 without displaying toxic effects, modulates glutamatergic and GABAergic neurotransmission in neuronal primary cultures (Walls et al., 2016) . Therefore, it can be claimed that the lack of effect of NAX-5055 on glucose and acetate metabolism was found using relevant concentrations of the analogue. Furthermore, galanin receptors are ubiquitously expressed throughout the central nervous system and GalR1 has been identified in cerebellum and brain cortex even at early developmental stages (Wickstr€ om et al., 2000) , ruling out the possibility that the absence of a functional galanin receptor may be hampering NAX-5055 effect on energy metabolism. Further, the effect of NAX-5055 on neurotransmitter release previously observed in the same types of neurons (Walls et al., 2016) corroborates the existence of galanin receptors in the neurons in culture.
Aiming at unraveling possible metabolic alterations underlying the changes in excitatory and inhibitory neurotransmission induced by NAX-5055, we studied brain cellular energy metabolism using 13 C-labeled substrates in primary cultures of neurons from mouse brain. The primary cultures used here consist of either predominantly cerebellar granule neurons or cerebral neocortical neurons with a minor contamination of glial cells and represent reliable models of glutamatergic and GABAergic neurons, respectively (Drejer et al., 1987; Drejer and Schousboe, 1989; Hertz et al., 1989) . These model systems have been extensively characterized at the histological, functional, and metabolic levels (Schousboe, 2012; Waagepetersen et al., 2005a; Waagepetersen et al., 2005b; Walls et al., 2014) . For instance, it has been repeatedly demonstrated that cultured cerebellar neurons release mainly glutamate in a Ca 21 -dependent fashion upon depolarization, whereas cultured neocortical neurons release GABA (Drejer et al., 1987; Pearce et al., 1981) . These neurons express enzymes and transporters associated specifically with either one of the neuronal phenotypes. Among these, glutamate decarboxylase (GAD) and GABA transporters in vesicles and plasma membranes have been predominantly observed in neocortical neurons whereas vesicular glutamate transporters are characteristic for cerebellar granule neurons (Borden, 1996; Chaudhry et al., 1998; Fremeau et al., 2004; Saito et al., 1974) . These cultured cells metabolize [U-13 C]glucose, making it possible to track labeled metabolites and map principal metabolic pathways under different experimental conditions. Using this approach we obtained consistent labeling patterns throughout the studied metabolites obtained from [U-13 C]glucose metabolism. Interestingly, an overall lower labeling was found in all metabolites after having exposed the cells to the superfusion paradigm compared to the incubation experiments. This difference might be due to the time the cells were exposed to the labeled substrate (40 min in the superfusion system vs. 60-min incubation). Alternatively, this might rely on the concentration gradient provided by the superfusion medium leading to continuous release and removal of the labeled metabolites while during incubation the metabolites are allowed to accumulate.
In addition, neurons co-cultured with astrocytes allowed us to investigate the effects of NAX-5055 on metabolic interactions between neurons and astrocytes. Previous studies have shown that co-cultures in which neurons grow together with astrocytes simulate the close relationship of these cell types in the brain and are therefore a suitable model for studying interactions between these cell types. For instance, in co-cultures of cerebral cortex incubated with [U-13 C]glucose or [1,2-13 C]acetate, a significant synthesis of glial glutamine from acetate, and subsequent transfer of glutamine to neurons and glutamine-derived GABA synthesis in the neuronal compartment was demonstrated (Leke et al., 2008) . Our finding that the complex metabolic landscape following [U- The results obtained in the present study also clearly indicate that galanin through activation of GalR1 receptors, does not directly affect cellular glucose utilization in the brain. Hence, our results imply that NAX-5055 mediates its anticonvulsant effect without changing cerebral glucose metabolism that may ultimately lead to unwanted side effects. Notably, using NAX-5055 as a pharmacological tool, GalR1 activation was shown to increase systemic blood glucose levels in mice and zebra fish (Flynn and White, 2015; Podlasz et al., 2016) . The peripheral hyperglycaemia induced by NAX-5055 might influence cerebral glucose metabolism in vivo as it has been demonstrated that glucose transporters and particularly GLUT-1 in the blood-brain barrier are regulated by ambient glucose concentrations (Vannucci et al., 1997) . This has raised some concerns regarding the use of systematically active GalR1-preferring analogues for the treatment of epilepsy in patients (Flynn and White, 2015) .
However, we demonstrated that NAX-5055 does not alter glucose metabolism in different brain cells which suggests that this neuropeptide might not induce adverse effects on cerebral energy metabolism in vivo. It should be acknowledged that one of the limitations of the present study is the lack of proper consideration of sex as a biological variable, because gender determination in the embryos and 7-day-old mice employed in the present study was not possible. However, the litters and groups of embryos used were assumed to include both females and males. Gender differences in brain energy metabolism in adults have been suggested previously (Geary and Lovejoy, 2007) . Nevertheless, the use of 3-4 different litters or groups of embryos should even out the gender differences.
Taken together, our findings suggest that NAX-5055 does not alter energy and neurotransmitter metabolism in the brain indicating that the inhibitory action of NAX-5055 on excitatory neurotransmission may not have a direct metabolic component. Previous studies suggest that GalR1 may be coupled to ATP-dependent K 1 (K ATP ) channels, likely Kir 6.2 (Stefani and Gold, 1998) . By binding to GalR1, galanin may be mediating K ATP channel opening in neurons, consequently hyperpolarizing the presynaptic terminal, and thus hampering neurotransmitter release (Karschin et al., 1997; Takigawa and Alzheimer, 1999; Zini et al., 1993) , or hyperpolarizing the post-synaptic terminal and interfering with the generation of action potentials. GalR1, via G o/a and phosphoinositide turnover has been shown to induce an overall inhibitory action through the blockade of L-and N-type voltage-gated Ca 21 channels Homaidan et al., 1991; Palazzi et al., 1991) , through direct coupling or inhibition of adenylate-cyclase. Therefore, it can be hypothesized that one or several of these mechanisms triggered by GalR1 activation can be underlying the inhibitory effect of NAX-5055 on excitatory activity. This is a matter that may be elucidated by further investigations.
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